1. Home
  2. ORKA vs GHLD Comparison

ORKA vs GHLD Comparison

Compare ORKA & GHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORKA
  • GHLD
  • Stock Information
  • Founded
  • ORKA 2004
  • GHLD 1960
  • Country
  • ORKA United States
  • GHLD United States
  • Employees
  • ORKA N/A
  • GHLD N/A
  • Industry
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • GHLD Finance: Consumer Services
  • Sector
  • ORKA Health Care
  • GHLD Finance
  • Exchange
  • ORKA Nasdaq
  • GHLD Nasdaq
  • Market Cap
  • ORKA 354.2M
  • GHLD 977.9M
  • IPO Year
  • ORKA N/A
  • GHLD 2020
  • Fundamental
  • Price
  • ORKA $12.60
  • GHLD $19.82
  • Analyst Decision
  • ORKA Strong Buy
  • GHLD Hold
  • Analyst Count
  • ORKA 8
  • GHLD 6
  • Target Price
  • ORKA $39.71
  • GHLD $16.30
  • AVG Volume (30 Days)
  • ORKA 341.3K
  • GHLD 146.5K
  • Earning Date
  • ORKA 08-15-2025
  • GHLD 08-07-2025
  • Dividend Yield
  • ORKA N/A
  • GHLD 2.52%
  • EPS Growth
  • ORKA N/A
  • GHLD 63.18
  • EPS
  • ORKA N/A
  • GHLD 0.71
  • Revenue
  • ORKA N/A
  • GHLD $1,131,796,000.00
  • Revenue This Year
  • ORKA N/A
  • GHLD $5.64
  • Revenue Next Year
  • ORKA N/A
  • GHLD $26.37
  • P/E Ratio
  • ORKA N/A
  • GHLD $27.85
  • Revenue Growth
  • ORKA N/A
  • GHLD 32.57
  • 52 Week Low
  • ORKA $5.49
  • GHLD $11.21
  • 52 Week High
  • ORKA $52.32
  • GHLD $20.15
  • Technical
  • Relative Strength Index (RSI)
  • ORKA N/A
  • GHLD 82.17
  • Support Level
  • ORKA N/A
  • GHLD $14.69
  • Resistance Level
  • ORKA N/A
  • GHLD $20.02
  • Average True Range (ATR)
  • ORKA 0.00
  • GHLD 0.26
  • MACD
  • ORKA 0.00
  • GHLD 0.09
  • Stochastic Oscillator
  • ORKA 0.00
  • GHLD 94.32

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

About GHLD Guild Holdings Company

Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.

Share on Social Networks: